Caudill Cortney 4

4 · HALOZYME THERAPEUTICS, INC. · Filed Mar 10, 2026

AI-generated summary of this filing

Updated Mar 10, 2026

Halozyme (HALO) COO Cortney Caudill Exercises Options, Sells Shares

What Happened

Cortney Caudill, COO of Halozyme Therapeutics (HALO), exercised stock options to acquire 21,546 shares at $33.51 per share (total cash outlay ~ $722,006). The filing also shows Caudill sold a total of 28,857 shares in open-market transactions for aggregate proceeds of about $1,955,159. The Form 4 lists matching derivative dispositions for the exercised amounts, indicating the exercised shares were promptly disposed (same-day sale/cashless-style treatment).

Key Details

Transaction dates: March 9, 2026 (major exercise and sales) and March 10, 2026 (small exercise and sale).
Options exercised: 20,000 shares on 3/9 and 1,546 shares on 3/10 at $33.51 each (total ~ $722,006).
Open-market sales: 17,900 shares @ weighted avg $67.75; 2,100 shares @ weighted avg $68.25; 8,857 shares @ weighted avg $67.64 — combined proceeds ≈ $1.955M. (Footnotes show sale price ranges across those lots; issuer can provide per-price breakdown on request.)
Filing timeliness: Report filed 2026-03-10 for transactions on 2026-03-09 and 2026-03-10 — appears timely.
Footnote on options: Options were granted Nov 1, 2023 and vest over 4 years (25% after 12 months, then monthly thereafter).

Context

Derivative code M = option exercise; S = open-market sale. The filing’s matching acquisition and derivative-disposition entries suggest the exercised shares were immediately sold (cashless or to cover exercise/taxes), rather than being retained as a net long position. Purchases (exercises) and sales occurred on consecutive days; total cash received from open-market sales exceeded the cash paid to exercise the options.
The filing is factual and does not state motivation. For post-transaction beneficial ownership (shares held after these trades) or exact per-lot sale prices, consult the full Form 4 (accession 0001159036-26-000033).

Form 4

Period: 2026-03-09

SVP, CHIEF OPERATING OFFICER

Transactions

Exercise/Conversion
Common Stock
2026-03-09$33.51/sh+20,000$670,200→ 34,366 total
Sale
Common Stock
[F1]
2026-03-09$67.75/sh−17,900$1,212,743→ 16,466 total
Sale
Common Stock
[F2]
2026-03-09$68.25/sh−2,100$143,329→ 14,366 total
Exercise/Conversion
Common Stock
2026-03-10$33.51/sh+1,546$51,806→ 15,912 total
Sale
Common Stock
[F3]
2026-03-10$67.64/sh−8,857$599,087→ 7,055 total
Exercise/Conversion
Option to Purchase Common Stock
[F4]
2026-03-09$33.51/sh−20,000$670,200→ 69,224 total
Exercise: $33.51Exp: 2033-11-01→ Common Stock (20,000 underlying)
Exercise/Conversion
Option to Purchase Common Stock
[F4]
2026-03-10$33.51/sh−1,546$51,806→ 67,678 total
Exercise: $33.51Exp: 2033-11-01→ Common Stock (1,546 underlying)

Footnotes (4)

[F1]Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.210 to $68.195. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F2]Represents a weighted average sales price per share. The shares were sold at prices ranging from $68.210 to $68.320. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F3]Represents a weighted average sales price per share. The shares were sold at prices ranging from $67.520 to $67.785. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
[F4]Grant to Reporting Person of options, exercisable over a 4-year period measured from the date of grant, 25% after 12 months, then 1/48th of the Option Shares per month thereafter. The date of grant was November 1, 2023.

Signature

/s/ James R. Oehler, Attorney-in-Fact|2026-03-10

1 file